Assoc. of Genomic Polymorphisms With Cancer Cachexia in Subjects With Panc Adenocarcinoma

Cachexia Clinical Trial

Official title:

Association of Genomic Polymorphisms With Cancer Cachexia in Subjects With Pancreatic Adenocarcinoma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05376592
• Other study ID #: IRB00083490
• Secondary ID: LCI-SUPP-PDAC-CC
• Status: Recruiting
• Start date: June 17, 2022
• Est. completion date: August 2028

Study information

• Verified date: April 2024
• Source: Wake Forest University Health Sciences
• Contact: Irissa Lu
• Phone: 980-442-7826
• Email: Irissa.Lu[@]atriumhealth.org
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

A major complication of pancreatic adenocarcinoma (PDAC) is cancer cachexia (CC) which is a complex syndrome characterized by skeletal muscle mass loss (with or without loss of fat mass) and progressive functional impairment not reversible by conventional nutritional support. It is estimated to occur in over 75% of patients with advanced PDAC, the highest incidence of all solid tumors, and contributes significantly to poor outcomes and mortality. Though there is overlap amongst the pathophysiologic studies evaluating CC in murine models of different tumor types, the high prevalence of CC within gastrointestinal (GI) malignancies and specifically PDAC suggest that dedicated studies evaluating polymorphisms in candidate genes specific to PDAC warrant further evaluation. The collection and analysis of specimens under this study will facilitate the identification and characterization of genomic polymorphisms associated with CC in PDAC patients. Subsequently, this data may help contribute towards diagnostic and therapeutic treatments that may improve patient outcomes.

Description:

This pilot study consists of a cohort of 100 locally advanced unresectable or metastatic PDAC subjects with a prospective analysis of biomarkers that may be associated with CC, a major negative prognostic factor in outcomes. The study protocol-directed assessments consist of four experimental measures (gene single nucleotide polymorphisms and available clinical information including weights, imaging review of sarcopenia, and select labs) used to determine factors that potentially contribute to CC in subjects with PDAC. Main confounding factors to be evaluated include stage of disease, receipt of anti-cancer therapies, and sites of metastatic disease. Specimens collected from PDAC patients treated at any LCI site may include blood or buccal swabs. Specimens may be collected during any participating LCI visit after the initial visit. Collected and processed specimens will be stored for analysis in the Biospecimen Repository of Levine Cancer Institute (BSR) and analyzed in the Nutrition Research Institute (NRI). All specimen results will remain deidentified. Personal health information will be collected on study participants and linked to results of genomic analysis but will be deidentified prior to any data analysis and presentation at scientific conferences, sharing with non-Atrium Health investigators and for publications.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: August 2028
• Est. primary completion date: August 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Subject must meet all of the following applicable inclusion criteria to participate in this

study:

• Written informed consent and HIPAA authorization for release of personal health information by the subject in accordance with the practices of the Levine Cancer Institute and Atrium Health. NOTE: HIPAA authorization will be included in the informed consent.
• Male or female patients age = 18 years at the time of consent
• Histological or cytological confirmation of pancreatic adenocarcinoma, with a diagnosis of locally advanced unresectable PDAC (LAPC) or metastatic pancreatic adenocarcinoma. LAPC is defined as per NCCN 16. Note: Subject can be enrolled at any time during their cancer course following histologic diagnosis.
• Able to provide a blood or buccal sample.

Exclusion Criteria:

• None

Related Conditions & MeSH terms

• Adenocarcinoma
• Cachexia
• Pancreas Adenocarcinoma

Locations

Country	Name	City	State
United States	Levine Cancer Institute	Charlotte	North Carolina

Sponsors (2)

Lead Sponsor	Collaborator
Wake Forest University Health Sciences	Atrium Health Levine Cancer Institute

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Cancer cachexia (CC)	A binary variable will be determined for each subject indicating if they have developed CC within 3 months after diagnosis as defined as weight loss of at least 5%.	approx. 3 months
Secondary	Cancer cachexia (CC)	A binary variable will be determined for each subject indicating if they have developed CC within 3 months after diagnosis as defined as weight loss of at least 10%.	approx. 3 months
Secondary	Sarcopenia	A binary variable will be determined for each subject indicating if they have developed sarcopenia at any point in time of or after diagnosis. Measurements of sarcopenia will be obtained via body composition analysis of available, routine CT and/or MRI imaging.	approx. 3 years
Secondary	Overall Survival (OS)	Overall survival is defined as the duration of time from the date of diagnosis to the date of death from any cause.	approx. 3 years
Secondary	One-year survival	One-year survival will be determined as a binary variable for each subject indicating if the subject is alive one year after the date of diagnosis.	approx. 1 year
Secondary	Progression free survival (PFS)	Progression free survival is defined as the duration from date of diagnosis to first occurrence of either progressive disease or death.	approx. 3 years